Loading...
01/11 03:34
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary indicates strong revenue guidance with a raised outlook, optimistic backlog conversion, and a strategic shift to faster growing therapeutic areas. Despite slower EBITDA growth, the overall sentiment is positive due to improved funding confidence, a strong pre-backlog position, and expected acceleration in hiring. While some uncertainties remain, particularly around cancellations and competition, the positive aspects outweigh them, suggesting a likely stock price increase over the next two weeks.
Revenue (Q3 2025) $659.9 million, a year-over-year increase of 23.7%. The increase was favorably impacted by higher reimbursable cost activity, particularly investigator sites, driven by a therapeutic mix shift to faster burning studies in areas with a higher concentration of reimbursable costs.
Net New Business Awards (Q3 2025) $789.6 million, a year-over-year increase of 47.9%. This resulted in a 1.20 net book-to-bill ratio.
Ending Backlog (as of September 30, 2025) Approximately $3 billion, an increase of 2.5% from the prior year.
EBITDA (Q3 2025) $148.4 million, a year-over-year increase of 24.9% compared to $118.8 million in Q3 2024. The increase was driven by productivity and lower employee-related costs, offset by higher reimbursable costs.
EBITDA Margin (Q3 2025) 22.5%, compared to 22.3% in the prior year period. Margins benefited from productivity and lower employee-related costs, offset by higher reimbursable costs.
Net Income (Q3 2025) $111.1 million, a year-over-year increase of 15.3% compared to $96.4 million in Q3 2024. Growth was below EBITDA growth due to a higher effective tax rate and lower interest income.
Net Income Per Diluted Share (Q3 2025) $3.86, compared to $3.01 in the prior year period.
Cash Flow from Operating Activities (Q3 2025) $246.2 million.
Net Days Sales Outstanding (Q3 2025) Negative 64.3 days.
Share Repurchases (Q3 2025) Approximately 14,649 shares for $4.5 million. Year-to-date, 2.96 million shares were repurchased for $912.9 million.
Revenue Growth: Revenue in Q3 2025 was $659.9 million, a 23.7% year-over-year increase. Revenue for the first nine months of 2025 was $1.82 billion, up 15.9%.
Backlog Growth: Ending backlog as of September 30, 2025, was approximately $3 billion, a 2.5% increase from the prior year. Approximately $1.84 billion of backlog is expected to convert to revenue in the next 12 months.
Net New Business Awards: Net new business awards in Q3 2025 increased 47.9% year-over-year to $789.6 million, resulting in a net book-to-bill ratio of 1.20.
EBITDA Growth: EBITDA in Q3 2025 was $148.4 million, a 24.9% increase from Q3 2024. Year-to-date EBITDA was $397.5 million, up 14.7%.
EBITDA Margin: EBITDA margin for Q3 2025 was 22.5%, slightly higher than 22.3% in Q3 2024. Year-to-date EBITDA margin was 21.8%, compared to 22% in the prior year.
Net Income: Net income in Q3 2025 was $111.1 million, a 15.3% increase from Q3 2024. Net income per diluted share was $3.86, compared to $3.01 in Q3 2024.
Cash Flow: Generated $246.2 million in cash flow from operating activities in Q3 2025.
Share Repurchase Program: Repurchased approximately 14,649 shares for $4.5 million in Q3 2025. Year-to-date repurchases totaled 2.96 million shares or $912.9 million. $821.7 million remains under the share repurchase authorization program.
2025 Guidance Update: Full-year 2025 revenue is expected to range from $2.48 billion to $2.53 billion, representing 17.6% to 20% growth over 2024. EBITDA is projected to range from $545 million to $555 million, reflecting 13.5% to 15.6% growth.
Cancellations: While cancellations were 'well behaved' in Q3, there is an implied risk that cancellations could increase in the future, potentially impacting net bookings and revenue.
Pass-through costs: Pass-through costs are expected to remain high, representing 41%-42% of revenue. This could pressure margins and profitability if not managed effectively.
Customer concentration: The top 5 and top 10 customers represent 23% and 33% of year-to-date revenue, respectively. This concentration poses a risk if any of these customers reduce or terminate their business with the company.
Tax rate and interest income: Net income growth was below EBITDA growth due to a higher effective tax rate and lower interest income, which could continue to impact profitability.
Backlog conversion: Backlog conversion was 23% of beginning backlog in Q3. If conversion rates slow, it could delay revenue realization and impact financial performance.
2026 Revenue Growth: Anticipated to grow in a low double-digit range off the updated 2025 full-year guidance.
2026 EBITDA Growth: Expected to grow at a high single-digit pace or greater.
Pass-Through Costs: Projected to remain high compared to historical levels, representing between 41% and 42% of revenue.
Backlog Conversion: Approximately $1.84 billion of backlog is projected to convert to revenue in the next 12 months.
2025 Revenue Guidance: Full-year revenue expected in the range of $2.48 billion to $2.53 billion, representing growth of 17.6% to 20% over 2024.
2025 EBITDA Guidance: Expected in the range of $545 million to $555 million, representing growth of 13.5% to 15.6% compared to 2024.
2025 Net Income Guidance: Forecasted in the range of $431 million to $439 million.
2025 Earnings Per Share (EPS): Expected to be in the range of $14.60 to $14.86.
Share Repurchase: During the quarter, we repurchased approximately 14,649 shares for $4.5 million. Year-to-date, we repurchased 2.96 million shares or $912.9 million. As of September 30, 2025, we had $821.7 million remaining under our share repurchase authorization program.
The earnings call summary indicates strong revenue guidance with a raised outlook, optimistic backlog conversion, and a strategic shift to faster growing therapeutic areas. Despite slower EBITDA growth, the overall sentiment is positive due to improved funding confidence, a strong pre-backlog position, and expected acceleration in hiring. While some uncertainties remain, particularly around cancellations and competition, the positive aspects outweigh them, suggesting a likely stock price increase over the next two weeks.
The earnings call summary indicates mixed signals: improved backlog growth and low cancellations are positive, but the weak win rate and dependency on low cancellations for future success are concerning. The Q&A reveals management's reluctance to provide specific long-term guidance, adding uncertainty. Despite improved productivity and revenue growth, reliance on pass-through revenue and potential headwinds in 2025 suggest caution. These factors, combined with management's vague responses, lead to a neutral sentiment, anticipating minimal stock price movement.
The earnings call reveals concerns about increased price competition, mixed project quality, and reliance on a few customers. EBITDA margins are decreasing, and there is uncertainty in backlog growth and bookings due to cancellations. Despite share repurchases, the Q&A highlights risks like funding issues and lack of clear guidance. These factors, combined with a decrease in net new business awards, suggest a negative sentiment likely affecting stock price.
The earnings call presents mixed signals with some positive financial metrics but several concerns. Revenue and net income showed growth, but there are significant risks: a low book-to-bill ratio, elevated backlog cancellations, and increased price competition. Guidance reflects modest growth, with potential operational challenges. The Q&A highlights concerns over cancellations, price competition, and client funding issues. Although share repurchases are positive, overall sentiment is negative due to operational uncertainties and external risks. Without market cap data, assume a moderate reaction, leading to a predicted stock price movement in the negative range (-2% to -8%).
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
